(Q43824337)

27 November 2017

Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer (English)

1 reference

27 November 2017

1 reference

1 reference

1 reference

Athanasios Dimopoulos

10

object named as

Dimopoulos MA

1 reference

27 November 2017

Papadimitriou CA

1

1 reference

27 November 2017

Kouroussis C

2

1 reference

27 November 2017

Moulopoulos LA

3

1 reference

27 November 2017

Vlahos G

4

1 reference

27 November 2017

Rodolakis A

5

1 reference

27 November 2017

Kiamouris C

6

1 reference

27 November 2017

Diakomanolis E

7

1 reference

27 November 2017

Gika D

8

1 reference

27 November 2017

Michalas S

9

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

27 November 2017

1 reference

27 November 2017

92

1 reference

27 November 2017

1856-1863

1 reference

27 November 2017

7

1 reference

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

27 November 2017

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Microcomputer-assisted univariate survival data analysis using Kaplan-Meier life table estimators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Ifosfamide and vinorelbine in advanced pretreated ovarian cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Vinblastine, ifosfamide, gallium nitrate, and filgrastim in platinum- and paclitaxel-resistant ovarian cancer: a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Sequences of taxol and cisplatin: a phase I and pharmacologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Combined carboplatin plus ifosfamide and cisplatin in patients with advanced ovarian carcinoma. A phase I-II study. GOCS (Gynecological Oncology Cooperative Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Phase II trial of ifosfamide and cisplatinum in advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Use of tumour markers in monitoring the course of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Ifosfamide and paclitaxel salvage chemotherapy for advanced epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Ifosfamide plus Cisplatin as Primary Chemotherapy of Advanced Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

New therapy for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

The calculation of received dose intensity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

One-sample multiple testing procedure for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

A combination of ifosfamide and mitoxantrone as salvage therapy in patients with advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Paclitaxel plus ifosfamide in advanced ovarian cancer: results of a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Phase II trial of high-dose cisplatin plus ifosfamide as first-line followed by carboplatin as second-line treatment in epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Prognostic value of CA 125 in advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

A risk model for ovarian carcinoma patients using CA 125: time to normalization renders second-look laparotomy redundant

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Early serum CA125 response and outcome in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Use of CA-125 response to predict survival parameters of patients with advanced ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in stage III and IV ovarian carcinoma: long-term results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011001%2992%3A7%3C1856%3A%3AAID-CNCR1702%3E3.0.CO%3B2-J

10.1002/1097-0142(20011001)92:7<1856::AID-CNCR1702>3.0.CO;2-J

21 January 2018

Identifiers

DOI

1 reference

27 November 2017

1 reference